M‐2 protocol for melphalan‐resistant and relapsing multiple myeloma

European Journal of Haematology

Volumn 40, Issue 2, 1988, Pages 168-173

  Cavo, Michele ^a   Galieni, Piero ^a   Tassi, Cristina ^a   Gobbi, Marco ^a   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

M 2 protocol; refractory multiple myeloma; salvage treatment

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; MELPHALAN; PREDNISONE; VINCRISTINE;

DRUG RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE AND BONES; BONE MARROW; CARMUSTINE; CYCLOPHOSPHAMIDE; DRUG RESISTANCE; HEMOGLOBINS; HUMAN; MELPHALAN; MIDDLE AGE; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PAIN; PREDNISONE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; VINCRISTINE;

EID: 0023943735     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1988.tb00816.x     Document Type: Article

References (20)

1. Treatment of refractory multiple myeloma and considerations for future therapy
2. Improved survival times in multiple myeloma treated with Melphalan, Prednisone, Cyclophosphamide, Vincristine and BCNU: M‐2 protocol
3. Drug‐resistant multiple myeloma. A trial with the M‐2 cyclic alkylating agent polychemotherapy
4. Proposed guidelines for protocol studies. II. Plasma cell myeloma
5. A clinical staging system for multiple myeloma
6. Immunoglobulin synthesis and tumor kinetics of multiple myeloma
7. Non parametric estimation from incomplete observations
8. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
9. Bone marrow transplantation in multiple myeloma
10. Cyclophosphamide vs. Melphalan in treatment of plasma cell myeloma
11. Plasma cell myeloma: response of melphalan resistant patients to high‐dose intermittent cyclophosphamide
12. Cross‐resistance to alkylating agents in multiple myeloma
13. Phase II study with methyl CCNU plus prednisone in previously treated alkylating agent resistant myeloma
14. Doxorubicin/BCNU chemotherapy for multiple myeloma in relapse
15. Vincristine BCNU, Doxorubicin and Prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group Study
16. Adriamycin, l,3‐bis(2‐chloroethyl)‐1‐Nitrosourea (BCNU, NSC # 409962), Cyclophosphamide plus Prednisone (ABC‐P) in Melphalan‐resistant multiple myeloma
17. Combination chemotherapy with intermittent 1–3‐bis (2‐chloroethyl)‐1‐Nitrosourea (BCNU), Cyclophosphamide and Prednisone for multiple myeloma
18. Prednisone pulse therapy for refractory myeloma
19. High‐dose melphalan with autologous bone marrow transplantation for multiple myeloma